Fava, M, Rosenbaum, JF. Anger attacks in depression.
. 1998; 8(Suppl 1): 59–63.
Perlis, RH, Fraguas, R, Fava, M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression Study. J Clin Psychiatry. 2005; 66(2): 159–166; quiz 147, 273–274.
Benazzi, F. Possible bipolar nature of irritability in major depressive disorder. J Clin Psychiatry. 2005; 66(8): 1072; author reply 1073.
Winkler, D, Pjrek, E, Kasper, S. Anger attacks in depression: evidence for a male depressive syndrome. Psychother Psychosom. 2005; 74(5): 303–307.
Perlis, RH, Fava, M, Trivedi, MH, et al. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009; 119(4): 282–289. Epub ahead of print Feb 5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312008/.
Fava, M, Hwang, I, Rush, AJ, et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010; 15(8): 856–867. Epub ahead of print Mar 10, 2009. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012558/.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
Zisook, S, Rush, AJ, Albala, A, et al. Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res. 2004; 129(2): 127–140.
Benazzi, F, Akiskal, H. Irritable-hostile depression: further validation as a bipolar depressive mixed state. J Affect Disord. 2005; 84(2–3): 197–207.
Perlis, RH, Uher, R, Ostacher, M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011; 68(4): 351–360. Epub ahead of print Dec 6, 2010. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794668/.
Judd, LL, Schettler, PJ, Akiskal, H, et al. Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes. J Affect Disord. 2012; 138(3): 440–448. Epub ahead of print Feb 6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677770/pdf/nihms468685.pdf.
Fisher, LB, Fava, M, Doros, GD, et al. The role of anger/hostility in treatment-resistant depression: a secondary analysis from the ADAPT–A study. J Nerv Ment Dis. 2015; 203(10): 762–768.
Pae, CU, Vohringer, PA, Holtzman, NS, et al. Mixed depression: a study of its phenomenology and relation to treatment response. J Affect Disord. 2012; 136(3): 1059–1061.
Judd, LL, Akiskal, HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73(1–2): 123–131.
Angst, J, Cui, L, Swendsen, J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010; 167(10): 1194–1201. Epub 2010 Aug 16. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145248/.
Benazzi, F, Akiskal, HS. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res. 2006; 141(1): 81–88.
Hoertel, N, Le Strat, Y, Angst, J, et al. Subthreshold bipolar disorder in a US national representative sample: prevalence, correlates, and perspectives for psychiatric nosography. J Affect Disord. 2013; 146(3): 338–347. Epub ahead of print Oct 3, 2012.
McIntyre, RS, Soczynska, JK, Cha, DS, et al. The prevalence and illness characteristics of DSM–5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2014; 172: 259–264. Epub ahead of print Oct 12.
Perugi, G, Angst, J, Azorin, JM, et al. Mixed features in patients with a major depressive episode: the BRIDGE–II–MIX study. J Clin Psychiatry. 2015; 76(3): e351–e358.
Ishibashi, T, Horisawa, T, Tokuda, K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181. Available at: http://jpet.aspetjournals.org/content/334/1/171.long.
Nakamura, M, Ogasa, M, Guarino, J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829–836. Epub ahead of print Jun 2.
Loebel, A, Cucchiaro, J, Xu, J, Sarma, K, Pikalov, A, Kane, JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1): 95–102. Epub ahead of print Apr 11. Available at: http://www.schres-journal.com/article/S0920-9964(13)00159-X/pdf.
Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400–407. Epub ahead of print Nov 10, 2015.
First, MB, Williams, J, Spitzer, RL, et al. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Clinical Trials Version (SCID–CT). New York: Biometrics Research, New York State Psychiatric Institute; 2007.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.
Guy, W. ECDEU Assessment Manual for Psychopharmacology. Publication no. ADM 76–338. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976: esp. 218–222.
Young, RC, Biggs, JT, Ziegler, VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978; 133: 429–435.
Smith, DJ, Forty, L, Russell, E, et al. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand. 2009; 119(4): 325–329. Epub ahead of print Dec 16, 2009.
Ionescu, DF, Fava, M, Kim, DJ, Baer, L, Shelton, RC, Cusin, C. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. Ther Adv Psychopharmacol. 2016; 6(1): 4–12. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749740/.
Khan, SA, Revicki, DA, Hassan, M, et al. Assessing the reliability and validity of the Sheehan Irritability Scale in patients with major depressive disorder. J Clin Psychiatry. 2016; 77(8): 1080–1086.